The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia: An in vitro study

Nishtman Dizeyi, Ingrid Yao Mattisson, Lena Ramnemark, Magnus Grabe4, Per‐Anders Abrahamsson

The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non‐bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH‐1 and WPMY‐1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production.